Acute respiratory distress syndrome (ARDS) is a devastating clinical syndrome with a considerable case fatality rate (30%-40%). Health disparities exist with African descent (AD) subjects exhibiting greater mortality than European descent (ED) individuals. Myosin light chain kinase is encoded by MYLK, whose genetic variants are implicated in ARDS pathogenesis and may influence ARDS mortality. As baseline population-specific epigenetic changes, that is, cytosine modifications, have been observed between AD and ED individuals, epigenetic variations in MYLK may provide insights into ARDS disparities. We compared methylation levels of MYLK cytosine-guanine dinucleotides (CpGs) between ARDS patients and intensive care unit (ICU) controls overall and by ethnicity in a nested case-control study of 39 ARDS cases and 75 non-ARDS ICU controls. Two MYLK CpG sites (cg03892735 and cg23344121) were differentially modified between ARDS subjects and controls (P , 0.05; q , 0.25) in a logistic regression model, where no effect modification by ethnicity or age was found. One CpG site was associated with ARDS in patients aged ,58 years, cg19611163 (intron 19, 20). Two CpG sites were associated with ARDS in EDs only, gene body CpG (cg01894985, intron 2, 3) and CpG (cg16212219, intron 31, 32), with higher modification levels exhibited in ARDS subjects than controls. Cis-acting modified cytosine quantitative trait loci (mQTL) were identified using linear regression between local genetic variants and modification levels for 2 ARDSassociated CpGs (cg23344121 and cg16212219). In summary, these ARDSassociated MYLK CpGs with effect modification by ethnicity and local mQTL suggest that MYLK epigenetic variation and local genetic background may contribute to health disparities observed in ARDS. (Translational Research 2017;180:12-21) Abbreviations: AD ¼ African descent; APACHE II ¼ acute physiology and chronic health evaluation II; ARDS ¼ acute respiratory distress syndrome; CpG ¼ cytosine-guanine dinucleotide; ED ¼ European descent; ICU ¼ intensive care unit; mQTL ¼ modified cytosine quantitative trait loci; MLCK ¼ myosin light chain kinase protein; MYLK ¼ myosin light chain kinase gene
INTRODUCTION
Acute respiratory distress syndrome (ARDS) is a devastating clinical syndrome defined by increased vascular leakiness and pulmonary edema resulting from underlying inflammatory disease conditions. Despite improvements in supportive therapy in the management of ARDS, ARDS mortality remains at 30%-40%. [1] [2] [3] [4] [5] [6] [7] [8] Previous US epidemiologic studies identified a health disparity between persons of African descent (AD) and European descent (ED) in mortality from ARDS, with ADs displaying a higher mortality rate than EDs. 9, 10 A study in the National Institutes of Health ARDS Network found higher mortality in persons of AD than ED before controlling for severity of illness at presentation. 11 In addition, a multicenter observational study found that ADs were less likely to develop the syndrome than EDs. 12 These studies of differences in ARDS susceptibility and mortality between these and other ethnic groups [10] [11] [12] [13] [14] highlight the need for elucidating the underlying mechanisms of ARDS health disparities. 15 The search for implicated genes involved in ARDS initially focused on studying gene expression in various preclinical ARDS models and human case-control studies. 16, 17 These studies combined with pathway analysis of vascular barrier-regulatory genes and genome-wide association studies led to the selection of MYLK (encoding myosin light chain kinase [MLCK] ) as an attractive ARDS candidate gene. 18 Genetic studies have demonstrated that MYLK haplotypes confer ethnic-specific susceptibility to sepsis and sepsis-or trauma-induced ARDS. [19] [20] [21] Functionally, MLCK regulates endothelial cell permeability via contractile pathways in response to inflammation. [22] [23] [24] Genetic haplotypes may affect MLCK expression and functionality, thus providing a mechanism for ARDS susceptibility. 25 Specifically, the nonmuscle isoform of MLCK has been implicated in increased lung injury in response to endotoxin administration both in vitro and in vivo. [26] [27] [28] [29] Furthermore, MYLK genetic variants in the form of single-nucleotide polymorphisms (SNPs) were found to contribute to nonmuscle isoform of MLCK expression and/or protein function as expression quantitative trait loci. 25, 30, 31 In addition to expression quantitative trait loci, epigenetic systems can also play a critical regulatory role in MYLK expression. However, the only MYLK epigenetic mechanism in ARDS explored to date involves microRNA-mediated regulation. [32] [33] [34] Another form of epigenetic regulation, that is, cytosine modifications (primarily DNA methylation of cytosines at cytosine-guanine dinucleotides [CpGs]) in MYLK, has not yet been evaluated for its potential role in the pathogenesis of ARDS. Interestingly, differentially modified cytosines in MYLK were recently identified in samples from healthy AD and ED individuals, thereby indicating a significant baseline variation in methylation between these 2 populations. 35, 36 Given the existence of natural genetic and epigenetic variations between individuals of ED and AD ancestry, understanding ethnicity-specific MYLK epigenetic regulation will enhance our knowledge of the molecular mechanisms underlying the observed ARDS disparities. 37 In this study, we hypothesized that ARDS-associated epigenetic modification of MYLK would present as differences in cytosine methylation levels when comparing ARDS patients with intensive care unit (ICU) controls, and secondly as ethnicity-specific epigenetic variants when comparing ARDS patients with ICU controls. Thirdly, we hypothesized that common genetic variants would contribute to the discovered epigenetic variants. 
MATERIALS AND METHODS

Translational Significance
Our nested case-control study found epigenetic modification variation of the well-described ARDS candidate gene, MYLK encoding myosin light chain kinase to be associated with ARDS patients and European ancestry. Epigenetic differences were partially associated with local genetic variation as well. Understanding the mechanisms of these ethnicity-specific and ARDS-associated modifications will be the next step in illuminating the genetic-epigenetic influences on health disparities in ARDS.
American-European
Consensus Conference definition. 38 Exclusion criteria in all patients included Hispanic heritage, diagnosis of cancer, history of organ transplant, or concurrent drug overdose to maintain a clear AD/ED comparison and to exclude known confounders of cytosine modification. 39 All samples were identified using a DNA identification number that was linked to demographic and clinical data, but not to personal identifiable data. Final distribution of cases and controls included 39 ARDS cases (18 EDs, 21 ADs) and 75 ICU controls (39 EDs, 36 ADs) for a total of 114 samples (Table I) .
vailable data for all patients included age, sex, and ethnicity. Clinical data available included the presence of sepsis, septic shock, systemic inflammatory response syndrome, and International Statistical Classification of Diseases and Related Health Problems 9 codes. Data including weight and height, smoking status, whether the patient died in the ICU or in hospital, and acute physiology and chronic health evaluation II (APACHE II) score were present for some but not all patients.
The study was carried out according to the Code of Ethics of the World Medical Association (Declaration of Helsinki), and all sample handling and analyses included in this study were determined to not involve ''human subjects'' as defined in 45 CFR 46.102(f) by the Office for the Protection of Research Subjects at the University of Illinois at Chicago, where sample handling and analyses were based. The original Chicago-based cohort sample collections were approved by the Institutional Review Board at each participating institution, were also carried out according to The Declaration of Helsinki, and informed consent was obtained from all patients before blood draw.
DNA sample preparation and DNA methylation quantification. For the Consortium for Investigating Intensive Care Unit Genetics cohort, DNA was isolated from individual patient's whole blood using the FlexiGene DNA Kit (Qiagen) according to the company protocol and subsequently maintained in 220 C to 280 C freezers. For the Genomic Association Studies cohort, DNA was isolated from individual patient's whole blood using the iPrep PureLink gDNA Blood Kit (Invitrogen) according to the company protocol and subsequently maintained in 220 C to 280 C freezers. For each selected sample, 800 ng DNA was submitted for 40 according to the manufacturers' protocols at the University of Chicago Genomics Core.
DNA methylation data processing. The 450K array data were processed according to a previous a publication. 35 Briefly, the M-values (log 2 ratio of the intensities of modified probe vs unmodified probe) 41 of CpG probes that passed quality control based on detection P-value (P , 0.01) across at least 95% of samples were summarized and batch corrected using combatting batch effects when combining batches of microarray data (ComBat). 42 We also detected 15 CpG probes in MYLK that are mapped to multiple loci in the human genome 43 or contain known common genetic variants based on the dbSNP v135. 44 The final test set comprised 37 CpG sites located within the MYLK gene. The genomic location groups (eg, promoter and gene body) were assigned according to the annotations provided by Illumina. The raw and processed 450K array data have been deposited into National Center for Biotechnology Information Gene Expression Omnibus database (accession number GSE67530).
Statistical analysis. Data analysis was performed with Statistical Analysis System 9.4 (Cary, NC) with a dichotomous dependent variable ARDS case or ICU control. Characteristics of the patient and control groups were compared using 1-way analysis of variance, Wilcoxon-Mann-Whitney, Chi-square, or Fisher's exact test, as appropriate (Table I) . Normally distributed M-values (logit transformation of the bvalue, ie, the ratio of methylated probe intensity and overall intensity) were used. 41 Logistic regression modeling with ARDS status as the dependent variable was used to assess the association of M-values of individual CpGs and potential effect modification by age (continuous), sex, and ethnicity by including interaction terms. For CpGs with significant (P , 0.10) ethnicity 3 M-value or age 3 M-value interaction terms, analysis was stratified by ethnicity or age (categories, ,58 and $58 years) as appropriate. Sex, age, and ethnicity were retained as covariates if the model was not already stratified by one of these variables. Including these covariates Abbreviations: AD, African descent; Adj, adjusted odds ratio; CI, confidence interval; Cr, crude unadjusted odds ratio; ED, European descent; ICU, intensive care unit; SE, standard error. AD and ED or ,58 y and $58 y, stratified odds ratios, indicating effect modification by ethnicity or age; b, regression coefficient. *Odds ratio with a nominal P-value ,0.05.
Fig 1. ARDS-associated and population-modified CpGs in MYLK.
(A) Locations of significant CpGs after controlling for age and sex and stratifying by ethnicity (cg01894985 and cg16212219), for sex and ethnicity and stratifying by age (cg19611163), and for sex, ethnicity, and age (cg03892735 and cg23344121), in logistic regression are indicated based on hg19. Vertical bars are exons; white triangles indicate significantly differentially modified CpG sites for ED ARDS cases vs ED ICU controls; striped triangle indicates a significant CpG for ,58 year-old ARDS vs ,58 year-old ICU controls; light gray triangles indicate significant CpG sites for ARDS cases vs ICU controls with no effect modification by age or ethnicity; arrows indicate higher modification (up arrow) or lower modification (down arrows) for ARDS cases vs ICU controls; numbers correlate to CpG probe ID numbers in the 450K array; and white stars indicate significant mQTL detected for 2 target CpG sites. (B) Significantly modified CpG sites for ARDS cases vs ICU controls controlling for age, sex, and ethnicity for which no significant M-value interaction terms were identified: cg03892735 and cg23344121 located in intron (4, 5) and exon 18, respectively. Effect plots of the probability that a case has ARDS (y-axis) according to M-value (x-axis). Open circles indicate observed case status (1 5 ARDS and 0 5 ICU control), line indicates the predicted probability across M-value, and shaded area indicates the 95% confidence limits for the predicted probabilities. (C) Significantly modified CpG sites for ARDS cases vs ICU controls among ED, controlling for age and sex: cg01894985 and cg16212219 located in intron (2, 3) and intron (31, 32) , respectively. Effect plots of the probability that a case has ARDS CpG site for ARDS cases vs ICU controls among those aged ,58 years, controlling for sex and ethnicity: cg19611163, located in intron (19, 20) . Effect plot of the probability that a case has ARDS (y-axis) according to M-value (x-axis). Plus signs indicate observed case status of patients aged ,58 years and open circles indicate observed case status of patients aged $58 years (1 5 ARDS and 0 5 ICU control), predicted probability across Mvalue is indicated by a dashed line for patients aged ,58 years and a solid line for patients aged $58 years, and the shaded areas (dark gray for ,58 years, light gray for $58 years) indicate the 95% confidence limits for the predicted probabilities. AD, African descent; ARDS, acute respiratory distress syndrome; CpG, cytosine-guanine dinucleotide; ED, European descent; ICU, intensive care unit; mQTL, modified cytosine quantitative trait loci.
= improved the fit of the model, as analyzed by the log likelihood when adding or removing terms and the Hosmer-Lemeshow goodness-of-fit test, and it is consistent clinically to control for these factors. [45] [46] [47] Effect modification was determined to be present if the interaction term was statistically significant in a logistic regression model and if the directionality or magnitude of association differed substantially. A nominal P-value of ,0.05 was used to identify differential CpGs, and the false discovery rate (FDR) was controlled by q-value for the crude unadjusted associations. 48 Some crude unadjusted associations did not meet the nominal P or FDR; however, stratified associations met the nominal P-value of ,0.05 requirement (Table II) .
Mapping of modified cytosine quantitative trait loci. Genotyping was performed on some of the DNA samples from our on-going genome-wide association studies (unpublished data, Garcia et al., 2016) using the Affymetrix Axiom Genome-Wide PanAFR (PanAfrican array) and Affymetrix Genome-Wide Human SNP Array 6.0 according to the manufacturer's recommendation at the University of Illinois DNA Services Facility. SNPs 1 Mbup-or down-stream from the MYLK gene were imputed to the 1000 Genomes Project 49 phase I integrated data using IMPUTE2. 50 Both directly genotyped and imputed SNPs with minor allele frequency .0.01 and missing rate ,25% (314 local SNPs, in total) were retained for modified cytosine quantitative trait loci (mQTL) mapping. Given that mQTL are predominantly local to target CpGs, 39 we included SNPs within 1 Mb of target CpGs in MYLK to map cis-acting (local) mQTL associated with the CpG modification levels using a linear regression model with sex as a covariate. FDR for mQTL mapping was controlled using the Benjamini-Hochberg (BH) approach. 51 
RESULTS
Comparisons of general characteristics, clinical characteristics, and comorbidities. ARDS cases and ICU controls had similar distributions of age and sex (Table I) . Clinical indices, including APACHE II scores and other variables associated with severity, were not statistically different between ARDS cases and ICU controls, except for occurrence of death during the current ICU or hospital stay (died ICU/ hospital) where ARDS cases had a higher odds of dying during the current stay compared with ICU controls (odds ratio 5 3.1; 95% CI, 1.22-7.82; P 5 0.014). The presence of comorbidities was also not statistically different between cases and controls except for pneumonia, being more common among ARDS cases; endocrine disease, being more common among ICU controls; and obesity, being less common among AD ARDS cases (Table I) .
Identification of CpGs in MYLK associated with ARDS. In logistic regression models, of the 33 unambiguous, high quality CpG probes located within MYLK for which ethnicity or age was found not to be an effect modifier for the methylation level, 2 CpG probes, cg03892735 (intron 4, 5) and cg23344121 (exon 18), were found to be significantly associated with ARDS status (P , 0.05; q , 0.25; Table II , Fig 1, B) . One CpG, cg19611163 (intron 19, 20) , for which age was found to be an effect modifier was analyzed in stratified logistic regression models and was found to be differentially methylated between ARDS patients and ICU controls among those aged ,58 years, but not those aged $58 years, where patients aged ,58 years were less methylated in ARDS cases compared with ICU controls (Table II, Fig 1, D) . Two CpGs for which ethnicity was found to be an effect modifier were evaluated in stratified logistic regression models and were found to be differentially methylated between ARDS subjects and ICU controls among EDs, but not ADs (Table II, Fig 1, C) . No modifications unique to AD ARDS cases were found. Of the MYLK cytosines modified in ED ARDS cases, cg01894985 (intron 2, 3) and cg16212219 (intron 31, 32) were more methylated in ARDS cases compared with ICU controls (Fig 1, A and C) .
Mapping of mQTL for ARDS-associated CpGs in
MYLK.
To assess the potential effect of genetic variation on cytosine modification, mQTL were mapped for the ARDS-associated and ethnicityinteracting CpGs in MYLK (Fig 1, A) . At the FDR corrected P , 0.05, there were 6 local SNPs (rs7650050, rs7630208, rs7652791, rs6780229, rs61281424, and rs59204624) (Table III) significantly associated with cg23344121 (P 5 6.84 3 10 25 ; r 2 5 0.23). All 6 SNPs were located in a linkage disequilibrium block (r 2 5 1). Eight local mQTL were detected for cg16212219 with a BH-adjusted Pvalue of ,0.05 (Fig 2, Table III ). For other tested CpGs, cg01894985, cg03892735, and cg19611163 no local mQTL were detected at a BH-adjusted P-value of ,0.10. 
DISCUSSION
This study identified 2 epigenetic variants, cg03892735 (intron 4, 5) and cg23344121 (exon 18), associated with ARDS in both ethnicities, 1 CpG site associated with ARDS only among those aged ,58 years and 2 CpG sites associated with ARDS only among EDs, when controlling for sex, age, and/or ethnicity as appropriate. The 2 MYLK CpGs associated with ARDS in EDs were more methylated (cg01894985 and cg16212219, located in the gene body) in ARDS cases compared with ICU controls. Of these 2 CpG sites, gene body cg16212219 was found to have 8 associated local SNPs, indicating possible contribution of local genetic variation to this epigenetic variant. Although we hypothesize that the observed variations in CpG modification may result in altered MYLK expression, future studies are necessary to test this hypothesis.
ARDS is a devastating clinical syndrome with a substantial mortality, annually affecting an estimated 190,600 people and attributing to 3.6 million hospital days in the United States. 1 Although AD patients display a higher mortality rate than ED patients even after adjusting for demographic and clinical variables, [9] [10] [11] in the present study, significant differences were not identified for in-hospital mortality between AD and ED ARDS patients. These results highlight several limitations of the study including the limited sample size because of the number of available samples and the applied exclusion criteria. Socioeconomic data and cause of death were not available. Height and weight and APACHE II score were also not available for all patients; therefore, it was not feasible to enter body mass index or APACHE II scores into the final regression analyses as it would dramatically reduce the number of samples analyzed. DNA was obtained from peripheral whole blood with multiple cell types, and complete blood cell counts were not available. As multiple physicians phenotyped the ARDS cases, there is a chance for misclassification of cases, 52 although the 1994 American-European Consensus Conference definition was used in chart evaluation. Type I error is possible because of the FDR of 25% and alpha threshold of 0.05 for more than 37 CpG sites evaluated. This analysis was not performed in a replicate manner, and it would be of benefit to reproduce these data in another cohort.
Although the functionality of the differentially modified CpGs identified in this study needs to be further studied, it is evident that there are novel epigenetic differences in the MYLK gene, associated with genetic variation and modified by ethnicity, between ARDS cases and ICU controls. Understanding these differences and further elucidating the effect of the specific SNPs and CpG modification levels on gene expression will be key next steps in mechanistically understanding the genetic-epigenetic effects on health disparities in ARDS.
